What are the symptoms of Stevens-Johnson syndrome associated with lamotrigine (Lamictal) and when should medical treatment be sought?

Symptoms of Stevens-Johnson Syndrome with Lamictal and When to Seek Medical Treatment

Stop lamotrigine immediately and seek emergency medical care if you develop any rash, fever, mouth sores, or eye symptoms—Stevens-Johnson syndrome (SJS) is a life-threatening emergency that most commonly occurs within the first 2-8 weeks of starting lamotrigine, with risk dramatically increased when combined with valproic acid. 1

Early Warning Signs Requiring IMMEDIATE Medical Attention

Prodromal symptoms (often appear before the rash):

• Fever, malaise, and upper respiratory symptoms
• Painful skin (cutaneous pain is a prominent early feature)
• Sore throat, sore eyes, or sore mouth 2

Skin manifestations:

• Any new rash (even if mild-appearing)
• Atypical target lesions or purpuric macules, typically starting on face, chest, upper torso, and proximal limbs
• Painful, tender skin that feels fragile to touch
• Blistering or peeling skin
• Positive Nikolsky sign (skin slides off with gentle lateral pressure)
• Hives 2, 1

Mucosal involvement (occurs early and is highly characteristic):

• Painful sores in the mouth, nose, or genitalia
• Erosive and hemorrhagic mucositis
• Eye involvement: purulent keratoconjunctivitis, eyelid swelling, ocular inflammation 2, 1

Systemic symptoms indicating severe reaction:

• High fever
• Swelling of face, eyes, lips, or tongue
• Swollen lymph glands
• Respiratory symptoms: cough, difficulty breathing, bloody sputum
• Gastrointestinal symptoms: diarrhea, abdominal distension 2, 1

Critical Risk Factors That Increase Your Danger

The risk of SJS is substantially elevated if you:

• Are taking valproate (Depakene/Depakote) with lamotrigine (19 of 38 cases in systematic review involved this combination) 1, 3
• Started with too high a dose or increased dose too rapidly 1
• Are within the first 2-8 weeks of treatment (most cases occur in first month) 1, 3, 4
• Are a child aged 2-16 years (higher risk, though Lamictal XR not approved under age 13) 1

When to Seek Medical Treatment

Go to the emergency department immediately if:

• You develop ANY rash while taking lamotrigine
• You have fever with skin symptoms
• You develop mouth sores, eye redness, or genital lesions
• Your skin becomes painful or tender
• You notice any blistering or skin peeling 2, 1

Do not wait to see if symptoms improve—SJS progresses rapidly and mortality ranges from <10% for SJS to 30% for toxic epidermal necrolysis (TEN). 2 The disease typically reaches maximum severity 5-7 days after onset, with extensive epidermal detachment leading to fluid loss, infection risk, and potential multiorgan failure. 2

What Happens at the Hospital

Upon presentation with suspected SJS, the medical team will:

• Immediately discontinue lamotrigine (this is the single most important intervention) 2
• Assess extent of skin involvement using body surface area calculations
• Evaluate for mucosal involvement of eyes, mouth, nose, and genitalia
• Perform skin biopsy to confirm diagnosis
• Calculate SCORTEN score to predict mortality risk 2
• Transfer to intensive care or burn unit if >10% body surface area involved 2

Common Pitfalls to Avoid

Never dismiss a mild rash as benign. There is no way to predict if a mild rash will progress to life-threatening SJS. 1 The FDA drug label explicitly warns that "a serious skin rash can happen at any time during your treatment with LAMICTAL XR, but is more likely to happen within the first 2 to 8 weeks of treatment." 1

Do not restart lamotrigine after stopping it for a rash without consulting your physician. Even if the rash resolved, rechallenge can trigger severe reactions. 1

Be aware that fever alone may not indicate infection in SJS—the disease process itself causes fever, complicating detection of secondary sepsis (the most common cause of death). 2 Additional signs like confusion, hypotension, reduced urine output, and decreased oxygen saturation must be monitored.

Recent case reports confirm that even with modern management including corticosteroids and immunoglobulins, mortality remains significant, with deaths reported even in 2024-2026 cases. 3, 4, 5 One 2026 case of a 67-year-old with mitochondrial disease died despite aggressive treatment, highlighting that certain patient populations face exceptionally high risk. 5

The cornerstone of survival is early recognition and immediate drug discontinuation, followed by transfer to specialized care. 2, 3